BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.

Both the FDA and EMA use a common technical document ... Sanofi since 2018 and is currently the medical director for Sanofi Genzyme UK & IE. He is an experienced pharmaceutical physician whose ...

Both of Genzyme's products are indicated for the treatment ... of their plant cell technology platform with this lead drug to perhaps provide a more cost-effective therapy,” he says, adding ...

Genzyme continued to drive growth for Sanofi ... analysts predicting sales of several billion dollars a year for the drug. Sanofi said the consolidation of Bioverativ, the haemophilia specialist ...

Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. The field of ...

After hours: February 18 at 5:17:49 PM EST Loading Chart for IGMS ...